Latest Pharma Insights
CDRH Report: 24 Voluntary Diversity Action Plans Filed In 2024
While the US FDA will not require diversity action plans for clinical trials for a while, some companies are already sending them in, a new FDA report to Congress shows.
Medtech Insight - January 11, 2025
While the US FDA will not require diversity action plans for clinical trials for a while, some companies are already sending them in, a new FDA report to Congress shows.
Medtech Insight - January 11, 2025
Pfizer Aims To Have First PD-1 Inhibitor Approved In Early NMIBC Setting
The drug maker announced positive topline Phase III results for its subcutaneous PD-1 inhibitor sasanlimab in first-line, BCG-naïve non-muscle invasive bladder cancer combined with BCG.
Scrip - January 10, 2025
The drug maker announced positive topline Phase III results for its subcutaneous PD-1 inhibitor sasanlimab in first-line, BCG-naïve non-muscle invasive bladder cancer combined with BCG.
Scrip - January 10, 2025
Stock Watch: Blockbuster Promise? Buyer Beware?
Big pharma is under pressure to find the next big thing, and new launches bring high hopes. But focusing on the number of new drugs approved each year may mislead on the sector’s success if profitability and significant sales elude a majority.
Scrip - January 10, 2025
Big pharma is under pressure to find the next big thing, and new launches bring high hopes. But focusing on the number of new drugs approved each year may mislead on the sector’s success if profitability and significant sales elude a majority.
Scrip - January 10, 2025
Crisis Deepens At IGM Biosciences As Autoimmune Gambit Fails
The company’s IgG antibody constructs have now failed in oncology and autoimmune disease, leaving it with few remaining strategic options.
Scrip - January 10, 2025
The company’s IgG antibody constructs have now failed in oncology and autoimmune disease, leaving it with few remaining strategic options.
Scrip - January 10, 2025
Scrip Asks… What Does 2025 Hold For Biopharma? Part 1: The State Of The Biopharma Industry
More than 40 industry executives shared their views on where the biopharma industry stands as it enters the new year. Innovation remains the sector’s driving force, but after two years of capital constraint, due diligence is key.
Scrip - January 10, 2025
More than 40 industry executives shared their views on where the biopharma industry stands as it enters the new year. Innovation remains the sector’s driving force, but after two years of capital constraint, due diligence is key.
Scrip - January 10, 2025
GSK-Backed Ouro Launches With $120m For T-Cell Engagers In Autoimmune Diseases
Ouro Medicines, founded by Monograph Capital and GSK and helmed by HI-Bio veterans, aims to reset the immune system in B-cell-mediated diseases with options that are not CAR-T therapies.
Scrip - January 10, 2025
Ouro Medicines, founded by Monograph Capital and GSK and helmed by HI-Bio veterans, aims to reset the immune system in B-cell-mediated diseases with options that are not CAR-T therapies.
Scrip - January 10, 2025
Finance Watch: Aviceda, Tenvie Among Flurry Of Pre-J.P. Morgan VC Financings
Private Company Edition: Biopharma firms revealed new VC funding to highlight progress ahead of the J.P. Morgan Healthcare Conference, including Aviceda’s $207.5m series C round, Tenvie’s $200m launch, a $115m series B for Aspect Biosystems and a €90m ($93.4m) series A for Orbis.
Scrip - January 10, 2025
Private Company Edition: Biopharma firms revealed new VC funding to highlight progress ahead of the J.P. Morgan Healthcare Conference, including Aviceda’s $207.5m series C round, Tenvie’s $200m launch, a $115m series B for Aspect Biosystems and a €90m ($93.4m) series A for Orbis.
Scrip - January 10, 2025
CDRH Report: 24 Voluntary Diversity Action Plans Filed In 2024
While the US FDA will not require diversity action plans for clinical trials for a while, some companies are already sending them in, a new FDA report to Congress shows.
Medtech Insight - January 11, 2025
While the US FDA will not require diversity action plans for clinical trials for a while, some companies are already sending them in, a new FDA report to Congress shows.
Medtech Insight - January 11, 2025
US Beauty Launch News: Target Doubles Down On Affordable Wellness Offerings, Coty Beauty Brands Launch Hi-Tech Mascaras
Target Corp. expands affordable wellness offerings in 2025 with 2,000 new items, including personal care and beauty. Separately, Coty Inc.’s Rimmel London brand launches Wonder Bond Bonding Serum Mascara and Covergirl introduces Lash Blast Supercloud Mascara featuring an ‘air-whipped’ emulsion formula; US Beauty Launch News.
HBW Insight - January 10, 2025
Target Corp. expands affordable wellness offerings in 2025 with 2,000 new items, including personal care and beauty. Separately, Coty Inc.’s Rimmel London brand launches Wonder Bond Bonding Serum Mascara and Covergirl introduces Lash Blast Supercloud Mascara featuring an ‘air-whipped’ emulsion formula; US Beauty Launch News.
HBW Insight - January 10, 2025
Alliance Pharma Set To Be Snapped Up By Private Equity
Offer valuing struggling UK consumer health player Alliance at £350m has the backing of the company's board of directors.
HBW Insight - January 10, 2025
Offer valuing struggling UK consumer health player Alliance at £350m has the backing of the company's board of directors.
HBW Insight - January 10, 2025
No Evidence To Support Probiotics For Gut Microbiota Recovery After Antibiotics
It is well established that antibiotics disrupt the human gut microbiome, but what is not so well established is the use of probiotics to restore it, find the authors of a recently published scientific literature review.
HBW Insight - January 10, 2025
It is well established that antibiotics disrupt the human gut microbiome, but what is not so well established is the use of probiotics to restore it, find the authors of a recently published scientific literature review.
HBW Insight - January 10, 2025
Clean Label Project’s ‘Wake Up Call’ About Protein Powder Purity Prompts Alarm From CRN
Testing by third-party lab accumulated 35,862 data points from 70 brands and 160 products as a benchmark for the study’s findings. Council for Responsible Nutrition criticized the study as lacking “critical context” and potentially “misleading consumers rather than empowering them.”
HBW Insight - January 10, 2025
Testing by third-party lab accumulated 35,862 data points from 70 brands and 160 products as a benchmark for the study’s findings. Council for Responsible Nutrition criticized the study as lacking “critical context” and potentially “misleading consumers rather than empowering them.”
HBW Insight - January 10, 2025
OCAC Director Katz’ Legacy: Moving Cosmetics Regulation Into Modern Era
Linda Katz, director of the Office of Cosmetics and Colors at the US Food and Drug Administration, is credited with leading efforts toward modernization of cosmetics regulations as she retires after 22 years at the helm.
HBW Insight - January 10, 2025
Linda Katz, director of the Office of Cosmetics and Colors at the US Food and Drug Administration, is credited with leading efforts toward modernization of cosmetics regulations as she retires after 22 years at the helm.
HBW Insight - January 10, 2025
UK Gabapentin Prices Shoot Up In December
UK prices for gabapentin almost trebled in December, according to the latest figures from WaveData.
Generics Bulletin - January 10, 2025
UK prices for gabapentin almost trebled in December, according to the latest figures from WaveData.
Generics Bulletin - January 10, 2025
ANI Continues To Spearhead FDA’s CGT Path With Prucalopride Launch
ANI Pharmaceuticals will compete with a product bringing in annual sales of more than $150m after launching the first generic with 180-day exclusivity via the FDA’s competitive generic therapy pathway.
Generics Bulletin - January 10, 2025
ANI Pharmaceuticals will compete with a product bringing in annual sales of more than $150m after launching the first generic with 180-day exclusivity via the FDA’s competitive generic therapy pathway.
Generics Bulletin - January 10, 2025
AEON’s Value Tanks As It Closes $20m Offering Amid Botox Biosimilar Aspirations
AEON Biopharma says it is planning for a biosimilar biological product development type 2 meeting in 2025 for its proposed biosimilar to the world-famous Botox brand, after raising much-needed capital to keep it afloat in 2025.
Generics Bulletin - January 10, 2025
AEON Biopharma says it is planning for a biosimilar biological product development type 2 meeting in 2025 for its proposed biosimilar to the world-famous Botox brand, after raising much-needed capital to keep it afloat in 2025.
Generics Bulletin - January 10, 2025
Podcast: Pre-JPM Biotech Dealmaking Panel
As we enter 2025, In Vivo convened a group of biotech executives for a wide-ranging conversation about dealmaking this year and the challenges and opportunities for companies in the cardiometabolic, longevity, radiopharmaceuticals and cancer spaces. Essential listening before JPM.
In Vivo - January 10, 2025
As we enter 2025, In Vivo convened a group of biotech executives for a wide-ranging conversation about dealmaking this year and the challenges and opportunities for companies in the cardiometabolic, longevity, radiopharmaceuticals and cancer spaces. Essential listening before JPM.
In Vivo - January 10, 2025